" /> Plutavimab - CISMeF





Preferred Label : Plutavimab;

NCIt synonyms : Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody STI-2020; Affinity Matured COVI-GUARD; Anti-SARS-CoV-2 S Protein Monoclonal Antibody STI-2020;

NCIt definition : A neutralizing human monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration, plutavimab specifically targets and binds to the S1 subunit of the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. The potency of STI-2020 was enhanced by an affinity maturation process.;

UNII : 12U14K0SR5;

CAS number : 2529854-88-2;

Drug name : COVI-AMG;

Molecule name : STI-2020; STI 2020; STI-2099;

NCI Metathesaurus CUI : CL1770593;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
11/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.